Literature DB >> 15328124

Impact of nelfinavir resistance mutations on in vitro phenotype, fitness, and replication capacity of human immunodeficiency virus type 1 with subtype B and C proteases.

Luis M F Gonzalez1, Rodrigo M Brindeiro, Renato S Aguiar, Helena S Pereira, Celina M Abreu, Marcelo A Soares, Amilcar Tanuri.   

Abstract

Human immunodeficiency virus type 1 subtype B and C proteases were manipulated to contain 90M, 88D, or 89L, and their in vitro biological properties were studied. We showed that D30N has significantly more impact in subtype C than in subtype B counterparts, accounting for the reported low prevalence of this mutation in patients failing nelfinavir-based regimens.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15328124      PMCID： PMC514783          DOI： 10.1128/AAC.48.9.3552-3555.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  19 in total

1.  Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.

Authors:  H C Côté; Z L Brumme; P R Harrigan
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

2.  Resistance-associated mutations in the human immunodeficiency virus type 1 subtype c protease gene from treated and untreated patients in the United Kingdom.

Authors:  P A Cane; A de Ruiter; P Rice; M Wiselka; R Fox; D Pillay
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

3.  Introduction of HIV-1 subtypes C, E and A into Austria.

Authors:  E Puchhammer-Stöckl; C Kunz; E Faatz; P Kasper; F X Heinz
Journal:  Clin Diagn Virol       Date:  1998-01

4.  Changes in the human immunodeficiency virus p7-p1-p6 gag gene in drug-naive and pretreated patients.

Authors:  Oscar Gallego; Carmen de Mendoza; Angélica Corral; Vincent Soriano
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

5.  Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein.

Authors:  S Peters; M Muñoz; S Yerly; V Sanchez-Merino; C Lopez-Galindez; L Perrin; B Larder; D Cmarko; S Fakan; P Meylan; A Telenti
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

6.  Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons.

Authors:  J G Garcia-Lerma; S Nidtha; K Blumoff; H Weinstock; W Heneine
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-06       Impact factor: 11.205

7.  Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy.

Authors:  Emanuele Nicastri; Loredana Sarmati; Gabriella d'Ettorre; Lucia Palmisano; Saverio G Parisi; Ilaria Uccella; Alessia Rianda; Ercole Concia; Vincenzo Vullo; Stefano Vella; Massimo Andreoni
Journal:  J Med Virol       Date:  2003-01       Impact factor: 2.327

8.  Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel.

Authors:  M S Hirsch; F Brun-Vézinet; R T D'Aquila; S M Hammer; V A Johnson; D R Kuritzkes; C Loveday; J W Mellors; B Clotet; B Conway; L M Demeter; S Vella; D M Jacobsen; D D Richman
Journal:  JAMA       Date:  2000-05-10       Impact factor: 56.272

9.  Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments.

Authors:  Thomas D Wu; Celia A Schiffer; Matthew J Gonzales; Jonathan Taylor; Rami Kantor; Sunwen Chou; Dennis Israelski; Andrew R Zolopa; W Jeffrey Fessel; Robert W Shafer
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

10.  Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir.

Authors:  A K Patick; M Duran; Y Cao; D Shugarts; M R Keller; E Mazabel; M Knowles; S Chapman; D R Kuritzkes; M Markowitz
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191
View more
  24 in total

Review 1.  2011 update of the drug resistance mutations in HIV-1.

Authors:  Victoria A Johnson; Vincent Calvez; Huldrych F Günthard; Roger Paredes; Deenan Pillay; Robert Shafer; Annemarie M Wensing; Douglas D Richman
Journal:  Top Antivir Med       Date:  2011-11

2.  Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy.

Authors:  Maria Mercedes Santoro; Claudia Alteri; Luigi Ronga; Philippe Flandre; Lavinia Fabeni; Fabio Mercurio; Roberta D'Arrigo; Caterina Gori; Guido Palamara; Ada Bertoli; Federica Forbici; Romina Salpini; Evangelo Boumis; Valerio Tozzi; Ubaldo Visco-Comandini; Mauro Zaccarelli; Margriet Van Houtte; Theresa Pattery; Pasquale Narciso; Andrea Antinori; Francesca Ceccherini-Silberstein; Carlo Federico Perno
Journal:  AIDS Res Hum Retroviruses       Date:  2012-04-18       Impact factor: 2.205

3.  Pulsed EPR characterization of HIV-1 protease conformational sampling and inhibitor-induced population shifts.

Authors:  Zhanglong Liu; Thomas M Casey; Mandy E Blackburn; Xi Huang; Linh Pham; Ian Mitchelle S de Vera; Jeffrey D Carter; Jamie L Kear-Scott; Angelo M Veloro; Luis Galiano; Gail E Fanucci
Journal:  Phys Chem Chem Phys       Date:  2016-02-17       Impact factor: 3.676

Review 4.  Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications.

Authors:  L Buonaguro; M L Tornesello; F M Buonaguro
Journal:  J Virol       Date:  2007-07-18       Impact factor: 5.103

Review 5.  HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

Authors:  Robert W Shafer; Jonathan M Schapiro
Journal:  AIDS Rev       Date:  2008 Apr-Jun       Impact factor: 2.500

6.  Drug resistance mutation profile and accumulation kinetics in human immunodeficiency virus-positive individuals infected with subtypes B and F failing highly active antiretroviral therapy are influenced by different viral codon usage patterns.

Authors:  A Waléria-Aleixo; A N Martins; M B Arruda; R M Brindeiro; R M Da-Silva; F F Nobre; D B Greco; A Tanuri
Journal:  Antimicrob Agents Chemother       Date:  2008-10-06       Impact factor: 5.191

7.  2019 update of the drug resistance mutations in HIV-1.

Authors:  Annemarie M Wensing; Vincent Calvez; Francesca Ceccherini-Silberstein; Charlotte Charpentier; Huldrych F Günthard; Roger Paredes; Robert W Shafer; Douglas D Richman
Journal:  Top Antivir Med       Date:  2019-09

8.  Differential persistence of transmitted HIV-1 drug resistance mutation classes.

Authors:  Vivek Jain; Maria C Sucupira; Peter Bacchetti; Wendy Hartogensis; Ricardo S Diaz; Esper G Kallas; Luiz M Janini; Teri Liegler; Christopher D Pilcher; Robert M Grant; Rodrigo Cortes; Steven G Deeks; Frederick M Hecht
Journal:  J Infect Dis       Date:  2011-04-15       Impact factor: 5.226

9.  Distinct resistance mutation and polymorphism acquisition in HIV-1 protease of subtypes B and F1 from children and adult patients under virological failure.

Authors:  Ana T Dumans; Cláudia C Barreto; André F Santos; Mônica Arruda; Thatiana M Sousa; Elizabeth S Machado; Ester C Sabino; Rodrigo M Brindeiro; Amílcar Tanuri; Alberto J Duarte; Marcelo A Soares
Journal:  Infect Genet Evol       Date:  2008-10-17       Impact factor: 3.342

10.  The challenge of antiretroviral drug resistance in HIV-1-infected children.

Authors:  Robert W Shafer
Journal:  J Pediatr (Rio J)       Date:  2009 Mar-Apr       Impact factor: 2.197
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.